A Phase IV Double-Blind Placebo-Controlled Multi-Center Trial To Study The Effects Of Evolocumab In Stage IV-V Chronic Kidney Disease: The Cardiovascular and Lipid-Lowering Effects Of Evolocumab In Advanced Chronic Kidney Disease Trial (EVO-CKD)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Chronic Kidney Disease
  • Age: Between 40 - 80 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants diagnosed with CKD Stage 4-5
    2. Low-density lipoprotein (LDL) =70 mg/dL and Treatment with maximal tolerated doses of a statin OR Statin intolerance defined as any history of intolerance or allergy to =1 statin
    3. Participants =60 years old are required to have =1 of the following cardiovascular risk factors:
      • History of CV disease
      • History of peripheral vascular disease
      • Diabetes
      • Smoking
      • Baseline LDL =160 mg/dL
      • Macroalbuminuria (albumin to creatinine ratio =300 mg/g on spot sample)

You may not be eligible for this study if the following are true:

    1. Participants who are expected survival less than 1 year
    2. Participants who are expected a transplant within 1 year
    3. Active liver disease
    4. Malignancy within 5 years
    5. Currently enrolled in another interventional study
    6. Female subject who has not used at least (1) effective method of birth control for at least 1 month prior to screening or (2) is not willing to use such a method during treatment and for an additional 15 weeks after the end of treatment
    7. Pregnant or breast-feeding participants
    8. Known sensitivity or intolerance to study medications



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.